Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial
Grilo C, Lydecker J, Gueorguieva R. Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial. Psychological Medicine 2023, 53: 7775-7784. PMID: 37366017, PMCID: PMC10751383, DOI: 10.1017/s0033291723001800.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderBinge-eating remissionAcute treatmentMaintenance treatmentBinge-eating frequencyDouble-blind placebo-controlled trialBehavioral weight loss therapyWeight lossCo-occurring obesitySuccessful acute treatmentPlacebo-controlled trialWeight loss therapySignificant additional weight lossSingle-site trialAdditional weight lossAcute efficacyRemission rateAdult patientsComorbid obesityBupropionInitial interventionPosttreatment assessmentRespondersPlaceboDoes Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder?
Yonkers K, Altemus M, Gilstad-Hayden K, Kornstein S, Gueorguieva R. Does Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder? Journal Of Clinical Psychopharmacology 2023, 43: 320-325. PMID: 37212651, PMCID: PMC10313784, DOI: 10.1097/jcp.0000000000001700.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderFunctional impairmentSymptom onsetPMDD symptomsDysphoric disorderAnger/irritabilityDaily treatmentActive treatmentFunctional outcomeClinical trialsFunctional improvementSecondary analysisCausal mediation analysisSertralineSeverity of problemsImpairmentNonsignificant direct effectDaily ratingsPlaceboTreatmentFace validitySymptomsIrritabilityDisordersSignificant indirect effect